Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations
- PMID: 17763411
- DOI: 10.1002/art.22842
Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations
Abstract
Objective: To examine the synthesis, processing, and secretion of interleukin-1beta (IL-1beta), as well as the clinical and biologic effects of IL-1 blockade, in patients with chronic infantile neurologic, cutaneous, articular (CINCA) syndrome and Muckle-Wells syndrome (MWS), in an effort to understand the molecular mechanisms linking mutations of the CIAS1 gene and IL-1beta hypersecretion, and the underlying response to IL-1 receptor antagonist (IL-1Ra).
Methods: Six patients with CINCA syndrome or MWS were treated with IL-1Ra and followed up longitudinally. Monocytes obtained from the patients and from 24 healthy donors were activated with lipopolysaccharide (LPS) for 3 hours, and intracellular and secreted IL-1beta levels were determined by Western blotting and enzyme-linked immunosorbent assay before and after exposure to exogenous ATP.
Results: LPS-induced IL-1beta secretion was markedly increased in monocytes from patients with CIAS1 mutations. However, unlike in healthy subjects, secretion of IL-1beta was not induced by exogenous ATP. Treatment with IL-1Ra resulted in a dramatic clinical improvement, which was paralleled by an early and strong down-regulation of LPS-induced IL-1beta secretion by the patients' cells in vitro.
Conclusion: Our results showed that the requirements of ATP stimulation for IL-1beta release observed in healthy individuals are bypassed in patients bearing CIAS1 mutations. This indicates that cryopyrin is the direct target of ATP and that the mutations release the protein from the requirement of ATP for activation. In addition, the dramatic amelioration induced by IL-1Ra treatment is at least partly due to the strong decrease in IL-1beta secretion that follows the first injections of the antagonist. These findings may have implications for other chronic inflammatory conditions characterized by increased IL-1beta.
Comment in
-
Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity.Arthritis Rheum. 2007 Sep;56(9):2817-22. doi: 10.1002/art.22841. Arthritis Rheum. 2007. PMID: 17763412 Review. No abstract available.
Similar articles
-
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.Arthritis Rheum. 2002 Dec;46(12):3340-8. doi: 10.1002/art.10688. Arthritis Rheum. 2002. PMID: 12483741 Free PMC article.
-
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.Arthritis Rheum. 2004 Feb;50(2):607-12. doi: 10.1002/art.20033. Arthritis Rheum. 2004. PMID: 14872505
-
Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies.Scand J Rheumatol. 2008 Sep-Oct;37(5):385-9. doi: 10.1080/03009740801978889. Scand J Rheumatol. 2008. PMID: 18609262
-
Rilonacept in the treatment of chronic inflammatory disorders.Drugs Today (Barc). 2009 Jun;45(6):423-30. doi: 10.1358/dot.2009.45.6.1378935. Drugs Today (Barc). 2009. PMID: 19649332 Review.
-
Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.Curr Rheumatol Rep. 2011 Apr;13(2):123-31. doi: 10.1007/s11926-011-0165-y. Curr Rheumatol Rep. 2011. PMID: 21538043 Free PMC article. Review.
Cited by
-
Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance.Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2835-40. doi: 10.1073/pnas.1424741112. Epub 2015 Feb 17. Proc Natl Acad Sci U S A. 2015. PMID: 25730877 Free PMC article. Clinical Trial.
-
Study of Serum Adiponectin and Interleukin-1β Levels in Women with Gestational Diabetes.Indian J Endocrinol Metab. 2022 Nov-Dec;26(6):581-588. doi: 10.4103/ijem.ijem_60_22. Epub 2022 Dec 20. Indian J Endocrinol Metab. 2022. PMID: 39005524 Free PMC article.
-
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.Ann Rheum Dis. 2017 Jan;76(1):303-309. doi: 10.1136/annrheumdis-2016-209335. Epub 2016 Jul 29. Ann Rheum Dis. 2017. PMID: 27474763 Free PMC article. Clinical Trial.
-
The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production.PLoS One. 2012;7(4):e34977. doi: 10.1371/journal.pone.0034977. Epub 2012 Apr 17. PLoS One. 2012. PMID: 22529966 Free PMC article.
-
Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation.Arthritis Rheum. 2011 Mar;63(3):830-9. doi: 10.1002/art.30170. Arthritis Rheum. 2011. PMID: 21360512 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
